Abstract
Uterine epithelial cancers are the most common type of gynecologic cancer in the United States. The American Cancer Society estimated 53,000 new cases of uterine cancers in 2014 with 8,600 deaths from advanced or recurrent cases, 99% of which are endometrial cancer. The 5-year survival rate of low-stage, low-grade endometrioid adenocarcinoma is greater than 90%. In contrast, advanced stage endometrioid adenocarcinomas and Type II (serous and carcinosarcoma) endometrial cancers have a much poorer prognosis, with the 5-year survival rate of advanced stage uterine carcinosarcoma as low as 9%. Together, these endometrial cancers with poor prognoses comprise almost half of all cases in the US, creating a significant medical obstacle for management. The authors present a review of endometrial cancer pathology, diagnosis and treatment. Included on the topic of treatment are: surgery, endocrine therapy, and chemotherapy with commentary on pertinent phase II and III clinical trials. The discussion covers single and multi-agent chemotherapy. Also covered are current clinical trials using targeted therapies such as mTOR inhibitors, angiokinase inhibitors, and HER2-directed agents. The review concludes with thoughts on future directions in therapeutic management of this disease.
Keywords: Endometrial cancer, endometrioid adenocarcinoma, serous, carcinosarcoma, chemotherapy, endocrine therapy, targeted therapy.
Current Cancer Therapy Reviews
Title:Treatment of Uterine Carcinomas
Volume: 11 Issue: 4
Author(s): Mary Chu, Estrelania Williams, D. Stave Kohtz, Tamara Kalir and David Fishman
Affiliation:
Keywords: Endometrial cancer, endometrioid adenocarcinoma, serous, carcinosarcoma, chemotherapy, endocrine therapy, targeted therapy.
Abstract: Uterine epithelial cancers are the most common type of gynecologic cancer in the United States. The American Cancer Society estimated 53,000 new cases of uterine cancers in 2014 with 8,600 deaths from advanced or recurrent cases, 99% of which are endometrial cancer. The 5-year survival rate of low-stage, low-grade endometrioid adenocarcinoma is greater than 90%. In contrast, advanced stage endometrioid adenocarcinomas and Type II (serous and carcinosarcoma) endometrial cancers have a much poorer prognosis, with the 5-year survival rate of advanced stage uterine carcinosarcoma as low as 9%. Together, these endometrial cancers with poor prognoses comprise almost half of all cases in the US, creating a significant medical obstacle for management. The authors present a review of endometrial cancer pathology, diagnosis and treatment. Included on the topic of treatment are: surgery, endocrine therapy, and chemotherapy with commentary on pertinent phase II and III clinical trials. The discussion covers single and multi-agent chemotherapy. Also covered are current clinical trials using targeted therapies such as mTOR inhibitors, angiokinase inhibitors, and HER2-directed agents. The review concludes with thoughts on future directions in therapeutic management of this disease.
Export Options
About this article
Cite this article as:
Chu Mary, Williams Estrelania, Stave Kohtz D., Kalir Tamara and Fishman David, Treatment of Uterine Carcinomas, Current Cancer Therapy Reviews 2015; 11 (4) . https://dx.doi.org/10.2174/1573394712666151119213759
DOI https://dx.doi.org/10.2174/1573394712666151119213759 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Blind Snipers: Relevant Off Target Effects of Non-chemotherapeutic Agents in Oncology: Review of the Literature
Reviews on Recent Clinical Trials Overcoming Drug Resistance by Enhancing Apoptosis of Tumor Cells
Current Cancer Drug Targets Intra- and Interdomain Flexibility in Matrix Metalloproteinases: Functional Aspects and Drug Design
Current Pharmaceutical Design Bv8-Prokineticins and their Receptors: Modulators of Pain
Current Pharmaceutical Biotechnology Too Much of a Good Thing: Suicide Prevention Promotes Chemoresistance in Ovarian Carcinoma
Current Cancer Drug Targets Dietary Patterns in Alzheimers Disease and Cognitive Aging
Current Alzheimer Research The Pharmacological Pathways of GnRH Mediating the Inhibition of Mammary Tumours: Implications in Humans and Domestic Animals
Current Medicinal Chemistry Role of TGF- β in the Tumor Stroma
Current Cancer Drug Targets A Review on Plant Flavonoids as Potential Anticancer Agents
Current Organic Chemistry Statins and Alkylphospholipids as New Anticancer Agents Targeting Lipid Metabolism
Anti-Cancer Agents in Medicinal Chemistry Selective Modifications of Steroids Performed by Oxidative Enzymes
Current Organic Chemistry The mTOR Signaling Network: Insights from Its Role During Embryonic Development
Current Medicinal Chemistry DMBA- Induced Breast Cancer: A Hormonal Camouflage
Current Cancer Therapy Reviews Spinophilin: A New Tumor Suppressor at 17q21
Current Molecular Medicine HSF1 as a Cancer Biomarker and Therapeutic Target
Current Cancer Drug Targets Pharmacophore Searching of Benzofuran Derivatives for Selective CYP19 Aromatase Inhibition
Letters in Drug Design & Discovery Eph Receptor Tyrosine Kinases in Tumor and Tumor Microenvironment
Current Pharmaceutical Design Advances in Targeting Insulin-like Growth Factor Signaling Pathway in Cancer Treatment
Current Pharmaceutical Design Alginate Based Nanocarriers for Drug Delivery Applications
Current Pharmaceutical Design Proniosomes in Transdermal Drug Delivery
Current Pharmaceutical Design